+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Anticoagulant Reversal Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026

  • ID: 4851508
  • Report
  • February 2019
  • Region: Global
  • 156 pages
  • Transparency Market Research
1 of 2

Global Anticoagulant Reversal Drugs Market: Overview

The global anticoagulant reversal drugs market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on product, distribution channel, and region. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region, thereby presenting a thorough analysis of the overall competitive scenario in the global anticoagulant reversal drugs market. 

Global Anticoagulant Reversal Drugs Market: Key Segments

In terms of product, the global anticoagulant reversal drugs market has been segmented into prothrombin complex concentrates, vitamin K, protamine, tranexamic acid, idarucizumab, AndeXXa, and others. Based on distribution channel, the global market has been classified into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment is anticipated to expand at a high CAGR during the forecast period. The market has been analyzed based on price variations, technology trend, and presence of key players. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. 

Global Anticoagulant Reversal Drugs Market: Regional Outlook

Geographically, the global anticoagulant reversal drugs market has been segmented into five major regions: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East (South Africa, GCC Countries, Israel, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries/sub-regions have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions. 

Companies Mentioned in Report

The report also profiles the major players in the market in terms of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Key companies profiled in the global anticoagulant reversal drugs market include Bausch Health Companies, Inc., Pfizer, Inc., Fresenius Kabi AG, Amneal Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, CSL Limited, Octapharma AG, Portola Pharmaceuticals, Inc., and Perosphere Pharmaceuticals, Inc. 

Note: Product cover images may vary from those shown
2 of 2
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights

2. Assumptions and Acronyms Used

3. Research Methodology

4. Executive Summary

5. Market Overview
5.1. Product Overview
5.2. Market Dynamics
5.2.1. Drivers
5.2.1.1. Rise in the prevalence of atrial fibrillation in aging population
5.2.1.2. Increase in the prevalence of ICH and GI hemorrhages
5.2.1.3. NTAP status for specific drugs
5.2.2. Restraints
5.2.2.1. Challenges associated with the development of anticoagulant reversal drugs
5.2.2.2. Risk associated with reversing anticoagulation
5.2.3. Opportunities
5.2.3.1. Unmet clinical needs
5.2.3.2. Untapped market in emerging economies
5.2.4. Global Anticoagulant Reversal Drugs Market Value (US$ Mn) Forecast, 2016-2026
5.2.5. Global Anticoagulant Reversal Drugs Market Outlook
5.2.6. Key Industry Developments
5.2.7. Regulatory Scenario
5.2.8. Reimbursement Scenario
5.2.9. Pipeline Analysis
5.2.10. Healthcare Overview

6. Global Anticoagulant Reversal Drugs Market Analysis, by Product
6.1. Introduction
6.2. Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Product
6.3. Global Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016-2026
6.3.1. Prothrombin Complex Concentrates (PCC)
6.3.2. Vitamin K
6.3.3. Protamine
6.3.4. Tranexmic Acid
6.3.5. Idarucizumab
6.3.6. Andexxa
6.3.7. Others
6.4. Market Attractiveness, by Product

7. Global Anticoagulant Reversal Drugs Market Analysis, by Distribution Channel
7.1. Introduction
7.2. Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel
7.3. Global Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016-2026
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Others
7.4. Market Attractiveness, by Distribution Channel

8. Global Anticoagulant Reversal Drugs Market Analysis, by Region
8.1. Introduction
8.2. Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region

9. North America Anticoagulant Reversal Drugs Market Analysis
9.1. Key Findings
9.2. North America Anticoagulant Reversal Drugs Market Value Forecast, by Country, 2016-2026
9.2.1. U.S.
9.2.2. Canada
9.3. North America Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016-2026
9.3.1. Prothrombin Complex Concentrates (PCC)
9.3.2. Vitamin K
9.3.3. Protamine
9.3.4. Tranexmic Acid
9.3.5. Idarucizumab
9.3.6. Andexxa
9.3.7. Others
9.4. North America Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016-2026
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Others
9.5. North America Market Attractiveness Analysis
9.5.1. By Country
9.5.2. By Product
9.5.3. By Distribution Channel

10. Europe Anticoagulant Reversal Drugs Market Analysis
10.1. Key Findings
10.2. Europe Anticoagulant Reversal Drugs Market Value Forecast, by Country/Sub-region, 2016-2026
10.2.1. U.K.
10.2.2. Germany
10.2.3. France
10.2.4. Italy
10.2.5. Spain
10.2.6. Rest of Europe
10.3. Europe Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016-2026
10.3.1. Prothrombin Complex Concentrates (PCC)
10.3.2. Vitamin K
10.3.3. Protamine
10.3.4. Tranexmic Acid
10.3.5. Idarucizumab
10.3.6. Andexxa
10.3.7. Others
10.4. Europe Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016-2026
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Others
10.5. Europe Market Attractiveness Analysis
10.5.1. By Country/Sub-region
10.5.2. By Product
10.5.3. By Distribution Channel

11. Asia Pacific Anticoagulant Reversal Drugs Market Analysis
11.1. Key Findings
11.2. Asia Pacific Anticoagulant Reversal Drugs Market Value Forecast, by Country/Sub-region, 2016-2026
11.2.1. China
11.2.2. Japan
11.2.3. India
11.2.4. Australia
11.2.5. Rest of Asia Pacific
11.3. Asia Pacific Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016-2026
11.3.1. Prothrombin Complex Concentrates (PCC)
11.3.2. Vitamin K
11.3.3. Protamine
11.3.4. Tranexmic Acid
11.3.5. Idarucizumab
11.3.6. Andexxa
11.3.7. Others
11.4. Asia Pacific Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016-2026
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Others
11.5. Asia Pacific Market Attractiveness Analysis
11.5.1. By Country/Sub-region
11.5.2. By Product
11.5.3. By Distribution Channel

12. Latin America Anticoagulant Reversal Drugs Market Analysis
12.1. Key Findings
12.2. Latin America Anticoagulant Reversal Drugs Market Value Forecast, by Country/Sub-region, 2016-2026
12.2.1. Brazil
12.2.2. Mexico
12.2.3. Rest of Latin America
12.3. Latin America Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016-2026
12.3.1. Prothrombin Complex Concentrates (PCC)
12.3.2. Vitamin K
12.3.3. Protamine
12.3.4. Tranexmic Acid
12.3.5. Idarucizumab
12.3.6. Andexxa
12.3.7. Others
12.4. Latin America Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016-2026
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Others
12.5. Latin America Market Attractiveness Analysis
12.5.1. By Country/Sub-region
12.5.2. By Product
12.5.3. By Distribution Channel

13. Middle East & Africa Anticoagulant Reversal Drugs Market Analysis
13.1. Key Findings
13.2. Middle East & Africa Anticoagulant Reversal Drugs Market Value Forecast, by Country/Sub-region, 2016-2026
13.2.1. GCC Countries
13.2.2. South Africa
13.2.3. Israel
13.2.4. Rest of Middle East & Africa
13.3. Middle East & Africa Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016-2026
13.3.1. Prothrombin Complex Concentrates (PCC)
13.3.2. Vitamin K
13.3.3. Protamine
13.3.4. Tranexmic Acid
13.3.5. Idarucizumab
13.3.6. Andexxa
13.3.7. Others
13.4. Middle East & Africa Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016-2026
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Others
13.5. Middle East & Africa Market Attractiveness Analysis
13.5.1. By Country/Sub-region
13.5.2. By Product
13.5.3. By Distribution Channel

14. Competitive Landscape
14.1. Competition Matrix
14.2. Anticoagulant Reversal Drugs Market Share Analysis, by Company (2018)
14.3. Company Profiles
14.3.1. Bausch Health Companies, Inc.
14.3.1.1. Company Overview (Headquarters, Business Segments, Employee Strength)
14.3.1.2. Financial Overview
14.3.1.3. Product Portfolio
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Pfizer, Inc.
14.3.2.1. Company Overview (Headquarters, Business Segments, Employee Strength)
14.3.2.2. Financial Overview
14.3.2.3. Product Portfolio
14.3.2.4. SWOT Analysis
14.3.3. Fresenius Kabi AG
14.3.3.1. Company Overview (Headquarters, Business Segments, Employee Strength)
14.3.3.2. Financial Overview
14.3.3.3. Product Portfolio
14.3.3.4. SWOT Analysis
14.3.4. Amneal Pharmaceuticals, Inc.
14.3.4.1. Company Overview (Headquarters, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Strategic Overview
14.3.5. Boehringer Ingelheim GmbH
14.3.5.1. Company Overview (Headquarters, Business Segments, Employee Strength)
14.3.5.2. Financial Overview
14.3.5.3. Product Portfolio
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. CSL Limited
14.3.6.1. Company Overview (Headquarters, Business Segments, Employee Strength)
14.3.6.2. Financial Overview
14.3.6.3. Product Portfolio
14.3.6.4. SWOT Analysis
14.3.7. Octapharma AG
14.3.7.1. Company Overview (Headquarters, Business Segments, Employee Strength)
14.3.7.2. Financial Overview
14.3.7.3. Product Portfolio
14.3.7.4. SWOT Analysis
14.3.8. Portola Pharmaceuticals, Inc.
14.3.8.1. Company Overview (Headquarters, Business Segments, Employee Strength)
14.3.8.2. Financial Overview
14.3.8.3. Product Portfolio
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. Perosphere Pharmaceuticals, Inc. (acquired by AMAG Pharmaceuticals, Inc.)
14.3.9.1. Company Overview (Headquarters, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll